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cancer cells (MCF-7) and normal fibroblast cells (3T3) 
 
ABSTRACT 
The present work involves the development of EA-Alg-AgNPs nanocomposite based on 
ellagic acid (EA) as active compound. Silver nitrate was taken as the metal precursor 
(AgNPs) and sodium alginate (Alg) as a reducing agent. The EA-Alg-AgNPs nanocomposite 
was characterized using transmission electron microscopy (TEM), zeta potential, and in vitro 
release kinetics. The particles thus obtained were spherical in shape and having an average 
particles size of 10 nm, zeta potentials of –8.2 mV, and the release kinetics of EA from 
nanocomposite was following Hixson-Crowell kinetics models with R 2 = 0.9956. The 
cytotoxicity potential of free EA, Alg-AgNPs and the EA-Alg-AgNPs nanocomposite may be 
determined using a normal mouse fibroblast cells (3T3) and breast cancer cells (MCF-7). EA-
Alg-AgNPs nanocomposite demonstrated a increased cytotoxicity effect when compared to 
free EA on MCF-7 cells with 15.3% cell viability at 128 μg/mL; compared to 33.5% cell 
viability in a direct EA exposure. It is worth mentioning the cytotoxicity of Alg-AgNPs 
against MCF-7 shows 28% viability at 128 μg/mL. 
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